Suppr超能文献

马查多-约瑟夫病及其他多聚谷氨酰胺脊髓小脑共济失调的小鼠模型。

Mouse models of Machado-Joseph disease and other polyglutamine spinocerebellar ataxias.

作者信息

Colomer Gould Veronica F

机构信息

Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.

出版信息

NeuroRx. 2005 Jul;2(3):480-3. doi: 10.1602/neurorx.2.3.480.

Abstract

Machado-Joseph disease (MJD), also called spinocerebellar ataxia type 3, is caused by mutant ataxin-3 with a polyglutamine expansion. Although there is no treatment available at present to cure or delay the onset of MJD, mouse models have been generated to facilitate the development of a therapy. In this review, the published reports on mouse models of MJD and other polyglutamine spinocerebellar ataxias are compared. Based on these studies, the following approaches will be discussed as candidate treatments for MJD: 1) interfering with the formation of the mutant ataxin-3 cleavage fragment and possibly aggregate or inclusions, 2) reducing the disease protein nuclear localization, and 3) decreasing mutant ataxin-3 expression in neurons.

摘要

马查多-约瑟夫病(MJD),也称为3型脊髓小脑共济失调,由具有多聚谷氨酰胺扩增的突变型ataxin-3引起。尽管目前尚无治愈或延缓MJD发病的治疗方法,但已建立了小鼠模型以促进治疗方法的开发。在本综述中,对已发表的关于MJD和其他多聚谷氨酰胺脊髓小脑共济失调小鼠模型的报告进行了比较。基于这些研究,将讨论以下作为MJD候选治疗方法的途径:1)干扰突变型ataxin-3裂解片段的形成以及可能的聚集或包涵体形成,2)减少疾病蛋白的核定位,3)降低神经元中突变型ataxin-3的表达。

相似文献

1
Mouse models of Machado-Joseph disease and other polyglutamine spinocerebellar ataxias.
NeuroRx. 2005 Jul;2(3):480-3. doi: 10.1602/neurorx.2.3.480.
6
Machado-Joseph disease/spinocerebellar ataxia type 3.
Handb Clin Neurol. 2012;103:437-49. doi: 10.1016/B978-0-444-51892-7.00027-9.
7
Machado-Joseph disease and other rare spinocerebellar ataxias.
Adv Exp Med Biol. 2012;724:172-88. doi: 10.1007/978-1-4614-0653-2_14.
9
Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.
J Neurochem. 2004 May;89(4):908-18. doi: 10.1111/j.1471-4159.2004.02369.x.
10

引用本文的文献

2
Glutamatergic Synapse Dysfunction in Neuromuscular Junctions Can Be Rescued by Proteostasis Modulation.
Front Mol Neurosci. 2022 Jul 15;15:842772. doi: 10.3389/fnmol.2022.842772. eCollection 2022.
3
Deubiquitylating enzymes and disease.
BMC Biochem. 2008 Oct 21;9 Suppl 1(Suppl 1):S3. doi: 10.1186/1471-2091-9-S1-S3.

本文引用的文献

3
Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice.
J Neurosci. 2004 Oct 6;24(40):8853-61. doi: 10.1523/JNEUROSCI.2978-04.2004.
4
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia.
Nat Med. 2004 Aug;10(8):816-20. doi: 10.1038/nm1076. Epub 2004 Jul 4.
5
Pharmacological treatments of cerebellar ataxia.
Cerebellum. 2004;3(2):107-11. doi: 10.1080/147342204100032331.
6
Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge.
Trends Pharmacol Sci. 2004 Feb;25(2):92-7. doi: 10.1016/j.tips.2003.12.004.
7
Allele-specific silencing of dominant disease genes.
Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7195-200. doi: 10.1073/pnas.1231012100. Epub 2003 Jun 2.
9
Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior.
Physiol Rev. 2002 Jul;82(3):637-72. doi: 10.1152/physrev.00004.2002.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验